# Center for Biospecimen Research & Development > **NIH NIH P30** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $148,755 ## Abstract PROJECT SUMMARY/ABSTRACT The Center for Biospecimen Research and Development (CBRD) is a state-of-the art human biorepository licensed by the State of New York and accredited by the College of American Pathologists (CAP). It is the NYU Langone Health (NYULH) central human biorepository serving Perlmutter Cancer Center (PCC) Investigators and NYU Grossman School of Medicine (NYUGSoM) investigators, and is active on all campuses (Manhattan, Brooklyn and Long Island). CBRD is directed by Dr. Andre L. Moreira, Professor of Pathology, a recognized expert in the field of Thoracic Pathology and tissue utilization, with 20 years of experience in Pathology and over 200 peer-reviewed publications. He is aided by an assistant director and 23 highly trained lab members. CBRD is overseen financially and administratively by the Division for Advanced Research Technologies (DART), has an Advisory Board composed of PCC members and other NYU faculty, and is subject to yearly surveys to ensure its alignment with the present and future needs of PCC members. We are critical to the 4 PCC Research Programs as we manage the collection, processing, and distribution of human tissue and biospecimens for all clinical and translational research. LabVantage is used for specimen tracking and annotation, which enables de- identification of specimens in order to comply with HIPPA and all other applicable laws. During the funding period, 97 PCC members across all four Research Programs used CBRD services. CBRD also supported 44 funded peer-reviewed grants, and 68 publications cited CBRD. The laboratory is located on the 2nd and 3rd floors of the Medical Science Building with 3,800 sq ft and 930 sq ft, respectively. Two satellite labs support NYULH- Brooklyn (582 sq ft) and NYULH-Long Island (243 sq ft). CBRD services include tissue collection and distribution (fresh and archival material), histopathology and immunohistology, digital pathology, biofluid processing and distribution, and extraction of nucleic acids from human biospecimens from enrolled patients under the IRB- approved Universal Mechanism Biobank Protocol. The Specific Aims of CBRD are 1) To maintain and expand the prospective NYULH Human Biospecimen Repository of tissue and blood samples with linked clinicopathological information of cancer patients who agree to the Universal Consent, 2) To process biospecimens, including by extracting nucleic acid, and provide specialized pathology and histopathology support as required for translational research projects by PCC members, and 3) To enable collaborations within the NYULH community and with outside institutions on human biospecimen-related research and to collect, process, and distribute human biospecimens of patients enrolled in investigator-initiated and industry-sponsored clinical trials. ## Key facts - **NIH application ID:** 10769328 - **Project number:** 2P30CA016087-43 - **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE - **Principal Investigator:** Andre Luis Moreira - **Activity code:** P30 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2024 - **Award amount:** $148,755 - **Award type:** 2 - **Project period:** 1996-12-01 → 2029-02-28 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10769328 ## Citation > US National Institutes of Health, RePORTER application 10769328, Center for Biospecimen Research & Development (2P30CA016087-43). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10769328. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*